EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain

Fernando Pérez-Ruiz, Carlos Crespo-Diz, Joan Antoni Schoenenberger-Arnaiz, Mónica Cerezales, Carlos Crespo, Marcelo Alejandro Guigini, José Ignacio Peinado-Fabregat, Mónica Climente-Martí

Farmacia Hospitalaria · 2025-09 · 49 (5) · 278-285

DOI: 10.1016/j.farma.2024.11.004 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Farmacia Hospitalaria, 2025-09. Verfasst von Fernando Pérez-Ruiz und 7 weiteren Autor:innen. Beteiligte Einrichtung: Chief of Rheumatology Division, Osakidetza, OSI-EEC, Cruces University Hospital, Barakaldo, Bizkaia, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Arthritis, Rheumatoid, Biosimilar Pharmaceuticals, Antirheumatic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Rheumatoid arthritis (RA) is the most common chronic inflammatory rheumatic disease, its management and morbidity impose a great burden to healthcare systems. Development and rollout of biological disease modifying anti-rheumatic drugs has contributed to improvements for patients, however, high costs have prevented them to be widely used. This is being addressed with biosimilars, with equal benefit-risk profile and reduced costs. The objective is to analyze the cost-effectiveness of subcutaneous biosimilar tocilizumab (bsTCZ) for patients with moderate-severe RA in Spain from a healthcare system perspective. METHODS: A Markov model was developed with a lifetime horizon including 5 health states: remission of the disease; low, moderate, or high activity; and death. A PICO-S-T search retrieved efficacy of treatments in meta-analysis and network meta-analysis, and was further complemented with published clinical trials. Pharmacological costs were obtained from the BotPlus database, and medical resources costs from regional tariffs. Deterministic and probabilistic sensitivity analysis were performed to validate the robustness of results. Incremental cost-effectiveness ratio (ICER) for cost/percentage of remission and cost/quality-adjusted life year (QALY) gain were calculated. RESULTS: Lifetime cost of bsTCZ was 183 741€ (lowest) versus comparative costs ranging from 184 317€ for infliximab to 201 972€ (highest) for certolizumab. QALYs were 13.74 for upadacitinib and 13.73 for sarilumab and tocilizumab with values between 13.53 and 13.72 for the comparators. ICERs as €/remission and €/QALY showed that bsTCZ was either dominant in most of the comparisons or the most cost-effective alternative. The sensitivity analysis showed that bsTCZ long term cost, and transition from low to moderate disease activity health status were the most influential factors. Moreover, bsTCZ was either dominant or cost-effective in all the comparisons. CONCLUSIONS: bsTCZ demonstrated to be a cost-effective and cost-saving alternative for the treatment of patients with RA in Spain when compared to all the available therapeutic alternatives.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedArthritis, RheumatoidBiosimilar PharmaceuticalsAntirheumatic AgentsHumansCost-Benefit AnalysisSpainMarkov ChainsInjections, SubcutaneousQuality-Adjusted Life YearsCost-Effectiveness Analysis

Stichwörter der Autor:innen

Artritis reumatoideBiosimilarCost-effectivenessCoste-efectividadICERRheumatoid arthritisTocilizumab

Substanzen

Antibodies, Monoclonal, HumanizedtocilizumabBiosimilar PharmaceuticalsAntirheumatic Agents

Autor:innen und Institutionen

  • Chief of Rheumatology Division, Osakidetza, OSI-EEC, Cruces University Hospital, Barakaldo, Bizkaia, Spain.
  • Chief of Hospital Pharmacy Department, Área Sanitaria Pontevedra e O Salnés / Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain.
  • Chief of Pharmacy Department, Regió Sanitària de Lleida, Lleida, Spain; Universitat de Lleida, Lleida, Spain.
  • Axentiva Solutions S.L., Oviedo, Spain.
  • Axentiva Solutions S.L., Barcelona, Spain.
  • Fresenius Kabi España, S.A.U, Barcelona, Spain.

Zitieren

APA

Pérez-Ruiz, F., Crespo-Diz, C., Schoenenberger-Arnaiz, J. A., Cerezales, M., Crespo, C., Guigini, M. A., Peinado-Fabregat, J. I., & Climente-Martí, M. (2025). Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain. Farmacia Hospitalaria, 49(5), 278-285. https://doi.org/10.1016/j.farma.2024.11.004

Vancouver

Pérez-Ruiz F, Crespo-Diz C, Schoenenberger-Arnaiz JA, Cerezales M, Crespo C, Guigini MA, et al. Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain. Farmacia Hospitalaria. 2025;49(5):278-285. doi:10.1016/j.farma.2024.11.004

BibTeX
@article{PrezRuiz2025,
  author = {Pérez-Ruiz, Fernando and Crespo-Diz, Carlos and Schoenenberger-Arnaiz, Joan Antoni and Cerezales, Mónica and Crespo, Carlos and Guigini, Marcelo Alejandro and Peinado-Fabregat, José Ignacio and Climente-Martí, Mónica},
  title = {Cost-effectiveness analysis of subcutaneous biosimilar tocilizumab in patients with rheumatoid arthritis in Spain},
  journal = {Farmacia Hospitalaria},
  year = {2025},
  volume = {49},
  number = {5},
  pages = {278--285},
  doi = {10.1016/j.farma.2024.11.004}
}
Kostenlos starten →